BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹722.70
- Market cap
- ₹11,375 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.0×Sector 46.1×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other capacity expansion announcements
All →Speciality Restaurants Capacity Expansion
Speciality Restaurants launched a new restaurant named WALTERS in Malad West, Mumbai, on October 28, 2026. The filing is a Reg 30 disclosure of a domestic restaurant launch with no monetary value stated.
- new restaurant outlets
- outlets
Goodluck India Capacity Expansion: ₹80 Cr Investment
Goodluck India's subsidiary Goodluck Defence and Aerospace approved adding Aerospace Components as a new line of business. The estimated investment is Rs 80 Crore, within a previously approved capital outlay.
- Value
- ₹80.00 Cr
Borosil Scientific Capacity Expansion: ₹70 Cr Investment
Borosil Scientific approved a Rs.70 Crore, 20 MT per day glass tubing furnace. Commercial production is expected by March 2028.
- Value
- ₹70.00 Cr
- Execution
- Commercial production expected by March 31, 2028
- borosilicate glass tubing production capacity
- 20.0 MT per day
Forbes Precision Tools and Machine Parts Capacity Expansion: ₹60 Cr Investment
Forbes Precision approved a Rs.60 Crore investment to add 10 lakh units annually within 1 to 1.5 years. Funding will combine internal accruals and debt.
- Value
- ₹60.00 Cr
- Execution
- 1 to 1.5 year
- production capacity
- 10.0 lakh units per annum
Diensten Tech Capacity Expansion
Diensten Tech's board approved incorporating a UAE subsidiary in IT consultancy, with the investment amount not yet fixed. Name, capital and incorporation date will be disclosed on completion.
- Execution
- Approximately 3 months from board approval, subject to regulatory approvals
Supreme Holdings & Hospitality (India) Capacity Expansion
Supreme Holdings approved a related-party joint development deal for a Panvel plot, pending shareholder approval. The project targets about 1 lakh sq ft saleable area.
- saleable area
- 100000.0 sq ft